Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.70 |
| ▸ | NAAA | Q02083 | 1/20 | 0.69 |
| ▸ | RAD52 | P43351 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | DGKA | P23743 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27918118 | 1.00 | HTR2C (0.70) | HTR2CNAAARAD52NPSR1DGKA | |
| SCHEMBL6380882 | 1.00 | HTR2C (0.70) | HTR2CNAAARAD52NPSR1DGKA | |
| SCHEMBL7780438 | 1.00 | HTR2C (0.70) | HTR2CNAAARAD52NPSR1DGKA | |
| SCHEMBL2269645 | 1.00 | HTR2C (0.70) | HTR2CNAAARAD52NPSR1DGKA | |
| SCHEMBL972977 | 1.00 | HTR2C (0.70) | HTR2CNAAARAD52NPSR1DGKA | |
| SCHEMBL410582 | 1.00 | HTR2C (0.70) | HTR2CNAAARAD52NPSR1DGKA | |
| SCHEMBL10626588 | 1.00 | HTR2C (0.70) | HTR2CNAAARAD52NPSR1DGKA | |
| SCHEMBL5153816 | 1.00 | HTR2C (0.70) | HTR2CNAAARAD52NPSR1DGKA | |
| SCHEMBL2763091 | 1.00 | HTR2C (0.70) | HTR2CNAAARAD52NPSR1DGKA | |
| SCHEMBL27505167 | 1.00 | HTR2C (0.70) | HTR2CNAAARAD52NPSR1DGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025080555-A1 | SUBSTITUTED AMIDINE IONIZABLE LIPID COMPOUNDS, METHODS OF PREPARATION THEREOF, LIPID NANOPARTICLES (LNPS) COMPRISING THE SAME, AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-04-17 | — | — | WO | claimed |
| CN-117987108-A | Polymer crosslinking system with siloxane structure for deep profile control | 中国海洋石油集团有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-116840387-A | Potential typing metabolic marker for nephrotic syndrome and metabolic marker related to lesion process and application of potential typing metabolic marker | 山西大学 | 2023-10-03 | — | — | CN | claimed |
| CN-114478870-B | Catalyst system for olefin polymerization and olefin polymerization method | 中国石油化工股份有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-114507303-B | External electron donor for olefin polymerization, catalyst system and olefin polymerization method | 中国石油化工股份有限公司 | 2023-05-05 | — | — | CN | claimed |
| US-20180311316-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | ADOCIA (FR) | 2018-11-01 | — | — | US | claimed |
| US-20170182131-A9 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | ADOCIA (FR) | 2017-06-29 | — | — | US | claimed |
| CN-103889442-B | Injectable solution of at least one basal insulin | 阿道恰公司 | 2016-12-28 | — | — | CN | claimed |
| EP-2741765-B9 | INJECTABLE SOLUTION OF AT LEAST ONE TYPE OF BASAL INSULIN | ADOCIA (FR) | 2016-09-28 | — | — | EP | claimed |
| EP-2741765-B1 | INJECTABLE SOLUTION OF AT LEAST ONE TYPE OF BASAL INSULIN | ADOCIA (FR) | 2016-03-30 | — | — | EP | claimed |
| US-20150250858-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | ADOCIA (FR) | 2015-09-10 | — | — | US | claimed |
| US-9089476-B2 | Injectable solution at pH 7 comprising at least one basal insulin whose PI is between 5.8 and 8.5 | ADOCIA (FR) | 2015-07-28 | — | — | US | claimed |
| CN-103889442-A | Injectable solution of at least one basal insulin | ADOCIA | 2014-06-25 | — | — | CN | claimed |
| CN-101664553-B | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN INC | 2013-08-21 | — | — | CN | claimed |
| US-20130065826-A1 | Injectable solution at pH 7 Comprising at least one basal insulin whose PI is between 5.8 and 8.5 | ADOCIA (FR) | 2013-03-14 | — | — | US | claimed |
| EP-1463823-B1 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN INC (US) | 2013-03-06 | — | — | EP | claimed |
| EP-4554959-A2 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | Pep2Tango Therapeutics Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025080555-A1 | SUBSTITUTED AMIDINE IONIZABLE LIPID COMPOUNDS, METHODS OF PREPARATION THEREOF, LIPID NANOPARTICLES (LNPS) COMPRISING THE SAME, AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-0119471-A2 | An active hydrogen-containing composition which provides mold release properties to a molded article, and a process for preparing molded polymeric products from the active hydrogen-containing composition | THE DOW CHEMICAL COMPANY (US) | 1984-09-26 | — | — | EP | disclosed |
| WO-1984003288-A1 | AN ACTIVE HYDROGEN-CONTAINING COMPOSITION WHICH PROVIDES MOLD RELEASE PROPERTIES TO A MOLDED ARTICLE, AN INTERNAL MOLD RELEASE COMPOSITION FOR PREPARING THE ACTIVE HYDROGEN-CONTAINING COMPOSITION, AND A PROCESS FOR PREPARING MOLDED POLYMERIC PRODUCTS FROM THE ACTIVE HYDROGEN-CONTAINING COMPOSITION | DOW CHEMICAL CO (US) | 1984-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182131-A9 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | IAPP, IGFBP5, INSR | HTR2C 3723/4885NAAA 3588/4885RAD52 4290/4885 |
| US-20180311316-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | IAPP, IGFBP5, INSR | HTR2C 3723/4885NAAA 3588/4885RAD52 4290/4885 |
| US-20150250858-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | IAPP, IGFBP5, INSR | HTR2C 3723/4885NAAA 3588/4885RAD52 4290/4885 |
| US-20130065826-A1 | Injectable solution at pH 7 Comprising at least one basal insulin whose PI is between 5.8 and 8.5 | IAPP, IGFBP5, INSR | HTR2C 3723/4885NAAA 3588/4885RAD52 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.